Table 1.
* Paclitaxel, Docetaxel, Vinflunine. ° Selected regimen collective, treated with 8 mg of Erd continuously. ∆ Pooled data. ▀ Data only available for n = 155 [40] + 125 [41]. ● Bladder cancer subgroup, treated with 10 mg SG/kg of body weight.
| Medication | CT * [42] | D ± R [43] | Erd ° [44] | EV ∆ [40,41,42] | SG ● [45,46] | ||
|---|---|---|---|---|---|---|---|
| D + R | D + P | ||||||
| Study phase | 4 | 3 | 2 | 1, 2, 3 | 2 | ||
| Number of patients (n) | 307 | 263 | 267 | 99 | 155 + 125 + 301 | 45 | |
| Median age in years (Range) | 68 (30–88) | 65 (59–72) | 66 (59–72) | 68 (36–87) | 68 (24–86) | 67 (49–90) | |
| Sex male, % | 75.6 | 80.9 | 80.5 | 76.8 | 75.2 | 91.1 | |
| ECOG = 0, % | 40.4 | 46.0 | 46.8 | 50.5 | 35.5 | 31.0 | |
| ECOG ≥ 1, % | 59.6 | 52.9 | 53.2 | 49.5 | 64.5 | 69.0 | |
| Sites of metastasis | Visceral, % | 81.7 | 69.2 | 70.4 | 78.8 | 80.2 | 73.3 |
| Lung, % | NA | 37.3 | 45.3 | 57.6 | 47.1 ▀ | 60.0 | |
| Liver, % | 30.9 | 29.7 | 25.8 | 20.2 | 34.9 | 33.3 | |
| Bone, % | NA | 21.3 | 19.9 | 21.2 | NA | NA | |
| Lymph nodes only, % | 9.2 | 15.6 | 15.7 | 21.2 | 10.2 | NA | |
| Prior therapies before study inclusion | CT platinum base, % | 100.0 | NA | 98 | 87.9 | 99.0 | 95.0 |
| CT cisplatinum-base, % | NA | 61.2 | 70.8 | NA | 74.6 ▀ | NA | |
| CT carboplatinum-base, % | NA | 36.9 | 28.8 | NA | 37.1 ▀ | NA | |
| CPI, % | 100.0 | 6.5 | 10.5 | 22.2 | 92.6 | 38.0 | |